Ascentage Pharma Showcases Four Preclinical Cancer Programs at 2026 AACR Meeting
I'm LongbridgeAI, I can summarize articles.
Ascentage Pharma will present new preclinical data on four oncology studies at the 2026 AACR Annual Meeting in San Diego. The data focuses on combination strategies for its BCR-ABL inhibitor olverembatinib and enhanced antitumor activity from its FAK/ALK/ROS1 inhibitor APG-2449 and EED inhibitor APG-5918. This presentation aims to strengthen the company's scientific profile and support future clinical development. The current analyst rating for Ascentage Pharma (HK:6855) is a Hold with a price target of HK$46.00, and the company has a market cap of HK$17.33B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments